Skip to content
Markets News
Stocks1 min read

Novartis Sets 5% Sales Growth Target Through 2031

Makkler Newsroom
November 19, 2026 · Based on reporting by GlobeNewswire, finanzen.net

The drugmaker expects annual sales growth of 5% through 2031 and raised peak sales guidance for three key medicines.

Key takeaways

  • Novartis expects net sales to grow at a 5% constant-currency CAGR from 2026 to 2031.
  • The company is targeting a core operating income margin of at least 40% by 2029.
  • Peak sales guidance rose for Kesimpta, Scemblix and Leqvio.

Novartis expects net sales to grow at a 5% constant-currency annual rate from 2026 to 2031, and said its core operating income margin is on track to return to at least 40% by 2029.

The company raised peak sales guidance for Kesimpta to $8 billion from $6 billion. Guidance for Scemblix and Leqvio increased to $5 billion each, from $4 billion.

Novartis said it now has nine marketed medicines with peak sales potential of $3 billion to $10 billion. It also expects more than 35 potentially submission-enabling trial readouts through 2031, and said 10 late-stage pipeline assets have multi-billion-dollar peak sales guidance.

The company expects its pipeline and marketed products to support sustained mid-single-digit sales growth over the longer term. Those projections are company guidance, and Novartis noted that actual results may differ.

As of 14:24 UTC, Novartis shares traded at CHF 127.80, down 2.8% since the previous close.

Topics
NOVNNovartis
Further reading

This article was produced with the help of AI technology. Based on reporting by the outlets listed above.

Comments (0)

Log in to join the discussion.Log in

No comments yet - be the first to weigh in.